BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasigna nilotinib: Phase III discontinued

Novartis discontinued the open-label, international Phase III ENESTg1 trial after an interim analysis by the study's independent DMC showed that Tasigna as first-line treatment for GIST was unlikely to demonstrate superiority to the company's Gleevec imatinib. The pharma planned to enroll >700 patients with newly diagnosed, unresectable and/or metastatic GIST in the trial....

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >